Literature DB >> 7501657

Implication of endogenous opioid system in the learned helplessness model of depression.

P Tejedor-Real1, J A Mico, R Maldonado, B P Roques, J Gibert-Rahola.   

Abstract

The involvement of opioid system on the learned helplessness model of depression was investigated. Animals preexposed to inescapable shocks were treated with either Met-enkephalin, Leu-enkephalin, morphine, imipramine, naloxone, RB 38A (a mixed inhibitor of enkephalin degrading enzymes), or RB 38B (a selective inhibitor of neutral endopeptidase EC 3.4.24.11). Stimulation of opioid system by either opioid agonists or enkephalin catabolism inhibitors reversed the escape deficit induced by shock pretreatment. In contrast, administration of naloxone potentiated the effect of inescapable shocks. Imipramine reduced the number of escape failures in this test, and this effect was antagonized by naloxone. These results point to the involvement of the endogenous opioid system in this model of depression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7501657     DOI: 10.1016/0091-3057(95)00067-7

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  13 in total

1.  Autoradiographic quantification of neurochemical markers of serotonin, dopamine and opioid systems in rat brain mesolimbic regions following chronic St John's wort treatment.

Authors:  Feng Chen; Amir H Rezvani; Andrew J Lawrence
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-23       Impact factor: 3.000

2.  Association Between Placebo-Activated Neural Systems and Antidepressant Responses: Neurochemistry of Placebo Effects in Major Depression.

Authors:  Marta Peciña; Amy S B Bohnert; Magdalena Sikora; Erich T Avery; Scott A Langenecker; Brian J Mickey; Jon-Kar Zubieta
Journal:  JAMA Psychiatry       Date:  2015-11       Impact factor: 21.596

3.  Reduced nucleus accumbens enkephalins underlie vulnerability to social defeat stress.

Authors:  Hyungwoo Nam; Ramesh Chandra; T Chase Francis; Caroline Dias; Joseph F Cheer; Mary Kay Lobo
Journal:  Neuropsychopharmacology       Date:  2019-05-27       Impact factor: 7.853

4.  The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors.

Authors:  Maria C Olianas; Simona Dedoni; Pierluigi Onali
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 5.  Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.

Authors:  Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2011-02-24       Impact factor: 6.505

6.  Mass spectrometry-based neuropeptidomics of secretory vesicles from human adrenal medullary pheochromocytoma reveals novel peptide products of prohormone processing.

Authors:  Nitin Gupta; Steven J Bark; Weiya D Lu; Laurent Taupenot; Daniel T O'Connor; Pavel Pevzner; Vivian Hook
Journal:  J Proteome Res       Date:  2010-10-01       Impact factor: 4.466

7.  Effect of the antidepressant nefazodone on the density of cells expressing mu-opioid receptors in discrete brain areas processing sensory and affective dimensions of pain.

Authors:  Antonio Ortega-Alvaro; Ignacio Acebes; Gonzalo Saracíbar; Enrique Echevarría; Luis Casis; Juan Antonio Micó
Journal:  Psychopharmacology (Berl)       Date:  2004-04-27       Impact factor: 4.530

Review 8.  Opioid receptors: distinct roles in mood disorders.

Authors:  Pierre-Eric Lutz; Brigitte L Kieffer
Journal:  Trends Neurosci       Date:  2012-12-06       Impact factor: 13.837

9.  Endogenous opioids upregulate brain-derived neurotrophic factor mRNA through delta- and micro-opioid receptors independent of antidepressant-like effects.

Authors:  Huina Zhang; Mary M Torregrossa; Emily M Jutkiewicz; Yong-Gong Shi; Kenner C Rice; James H Woods; Stanley J Watson; M C Ko
Journal:  Eur J Neurosci       Date:  2006-02       Impact factor: 3.386

10.  The anxiolytic- and antidepressant-like effects of ATPM-ET, a novel κ agonist and μ partial agonist, in mice.

Authors:  Qian Wang; Yu Long; Ai Hang; Gui-Ying Zan; Xiao-Hong Shu; Yu-Jun Wang; Jing-Gen Liu
Journal:  Psychopharmacology (Berl)       Date:  2016-04-26       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.